Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Cagrilintide (AM833, CAS 1415456-99-3) activates brainstem amylin (AMY1R–3R) and calcitonin (CTR) receptors via a cyclic disulfide architecture, operating independently of the GLP-1R/GIPR/GCGR incretin pathways targeted by Retatrutide, Tirzepatide, and Semaglutide.
- Cagrilintide is a 37-residue acylated amylin analogue with a critical Cys2–Cys7 intramolecular disulfide bridge and C20 fatty diacid.
- Amylin receptors are heterodimers of the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1–3).
- Unlike Retatrutide or Tirzepatide, Cagrilintide acts outside the incretin GPCR family—enabling additive co-formulation research with Semaglutide (CagriSema) or Tirzepatide.
- Cagrilintide requires mildly acidic buffer control (pH ~4.0) to prevent amyloidogenic fibril aggregation during aqueous bench storage.
| Cagrilintide CAS / MW | 1415456-99-3 | 4409.04 g/mol | Cys2–Cys7 Disulfide |
|---|---|
| Primary Receptors | Calcitonin Receptor (CTR) + RAMP1/2/3 (AMY1R–3R) |
| Retatrutide CAS / MW | 2381089-83-2 | 4731.33 g/mol | Linear Acylated 39-aa |
| Incretin Comparison | Semaglutide (GLP-1R) | Tirzepatide (GLP-1R/GIPR) | Retatrutide (Triple) |
| Fibrillation Prevention | Proline substitutions at 25/28/29 + low-agitation acidic/neutral prep |
| Analytical Verification | ≥99.0% RP-HPLC + ESI-MS disulfide closure verification (-2 Da) |
1. Structural Chemistry of Cagrilintide (AM833)
Cagrilintide (CAS 1415456-99-3, MW 4409.04 g/mol) is a 37-amino acid acylated analogue of human amylin (islet amyloid polypeptide, IAPP). Native human amylin aggregates rapidly into insoluble β-sheet fibrils in aqueous solution. Cagrilintide overcomes fibrillation through rat-derived proline substitutions (Pro25, Pro28, Pro29), an N-terminal C20 fatty-diacid moiety attached via a γ-glutamic acid spacer for albumin binding, and a conserved Cys2–Cys7 intramolecular disulfide loop essential for receptor recognition.
2. Cagrilintide vs Retatrutide: Orthogonal Receptor Families
Comparing Cagrilintide vs Retatrutide contrasts two completely distinct neuroendocrine signaling axes. Retatrutide engages Class B incretin/glucagon GPCRs (GLP-1R, GIPR, GCGR) expressed across pancreatic islets, adipose tissue, and hepatocytes. Cagrilintide acts as a dual amylin and calcitonin receptor agonist (DACRA), binding CTR/RAMP1–3 heterodimers localized in the area postrema and nucleus tractus solitarius to modulate gastric emptying and satiety cascades independently of incretin signaling.
3. Co-Administration Models: Cagrilintide + Semaglutide vs Tirzepatide
Because amylin receptors do not compete with GLP-1R or GIPR binding sites, researchers study co-formulations such as Cagrilintide + Semaglutide alongside single-molecule multi-agonists like Tirzepatide and Retatrutide. Note a critical formulation constraint: Cagrilintide achieves optimal chemical stability near pH 4.0, whereas Semaglutide is formulated near pH 7.4—meaning separate stock vials or carefully validated dual-chamber reconstitution protocols prevent pH-induced deamidation or precipitation.
4. Disulfide Integrity & Reconstitution Controls for Cagrilintide
Never expose Cagrilintide to reducing agents (DTT, TCEP) or alkaline buffers above pH 8.0, which cleave the Cys2–Cys7 disulfide bridge and abolish CTR/AMY receptor potency. Equilibrate sealed lyophilized vials inside a desiccator before slow-wall diluent addition, avoid vortexing to prevent interfacial fibrillation, and store reconstituted stocks refrigerated at 2°C–8°C.
Peer-Reviewed References & Analytical Standards
- Kruse T. et al. (2021). Development of Cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry, 64(15), 11183–11194. [PMID: 34288673 ↗]
- Frias J.P. et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg (CagriSema). The Lancet, 402(10403), 720–730. [PMID: 37364590 ↗]
- Coskun T. et al. (2022). LY3437943 (Retatrutide), a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 34(9), 1234–1247. [PMID: 35985340 ↗]
Referenced Laboratory Research Reagents
Batch-verified SwissLab catalog entries cited in this monograph
All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.